文章：

释放Yes相关蛋白在乳腺癌铁死亡与耐药性中的潜力，特别聚焦于治疗策略

Unleashing the Power of Yes-Associated Protein in Ferroptosis and Drug Resistance in Breast Cancer, with a Special Focus on Therapeutic Strategies

原文发布日期：6 December 2023

DOI: 10.3390/cancers15245728

类型: Article

开放获取: 是

英文摘要：

The YAP protein is a critical oncogenic mediator within the Hippo signaling pathway and has been implicated in various cancer types. In breast cancer, it frequently becomes activated, thereby contributing to developing drug-resistance mechanisms. Recent studies have underscored the intricate interplay between YAP and ferroptosis within the breast tumor microenvironment. YAP exerts a negative regulatory effect on ferroptosis, promoting cancer cell survival and drug resistance. This review offers a concise summary of the current understanding surrounding the interplay between the YAP pathway, ferroptosis, and drug-resistance mechanisms in both bulk tumor cells and cancer stem cells. We also explore the potential of natural compounds alone or in combination with anticancer therapies for targeting the YAP pathway in treating drug-resistant breast cancer. This approach holds the promise of enhancing the effectiveness of current treatments and paving the way for developing novel therapeutics.

摘要翻译： 

YAP蛋白是Hippo信号通路中的关键致癌介质，与多种癌症类型密切相关。在乳腺癌中，YAP常被激活，从而促进耐药机制的形成。近期研究揭示了YAP与铁死亡在乳腺肿瘤微环境中的复杂相互作用。YAP对铁死亡具有负向调控作用，能够促进癌细胞存活并增强其耐药性。本综述简要总结了目前关于YAP通路、铁死亡以及肿瘤细胞与癌症干细胞中耐药机制相互作用的研究进展。同时，我们探讨了天然化合物单独或联合抗癌疗法靶向YAP通路治疗耐药性乳腺癌的潜力。这一策略有望提升现有治疗方案的疗效，并为开发新型治疗方法开辟道路。

原文链接：

Unleashing the Power of Yes-Associated Protein in Ferroptosis and Drug Resistance in Breast Cancer, with a Special Focus on Therapeutic Strategies